Taxotere [docetaxel] plus concurrent radiotherapy after induction chemotherapy for squamous cell carcinoma of the head and neck (TAXT-XRT)
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2017
At a glance
- Drugs Docetaxel (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- Acronyms TAXT-XRT
- 17 Jan 2017 Status changed from active, no longer recruiting to completed.
- 27 Sep 2005 New trial record.